Related Experiment Video
Updated: Feb 13, 2026
Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery
Published on: June 23, 2020
Targeted Delivery of Auristatin-Modified Toxins to Pancreatic Cancer Using Aptamers
Christina Kratschmer1, Matthew Levy1
1Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY, USA.
Abstract:
Pancreatic cancer is one of the most lethal malignancies. Treatment with the first-line agent, gemcitabine, is often unsuccessful because it, like other traditional chemotherapeutic agents, is non-specific, resulting in off-target effects that necessitate administration of subcurative doses. Alternatively, monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are highly toxic small molecules that require ligand-targeted delivery. MMAE has already received FDA approval as a component of an anti-CD30 antibody-drug conjugate, brentuximab vedotin. However, in contrast to antibodies, aptamers have distinct advantages. They are chemicals, which allows them to be produced synthetically and facilitates the rapid development of diagnostics and therapeutics with clinical applicability. In addition, their small size allows for enhanced tissue distribution and rapid systemic clearance. Here, we assayed the toxicity of MMAE and MMAF conjugated to an anti-transferrin receptor aptamer, Waz, and an anti-epidermal growth factor receptor aptamer, E07, on the pancreatic cancer cell lines Panc-1, MIA PaCa-2, and BxPC3. In vitro, our results indicate that these aptamers are a viable option for the targeted delivery of toxic payloads to pancreatic cancer cells.
Insights
Aptamers conjugated to toxic payloads show promise for targeted pancreatic cancer therapy. These novel drug delivery systems offer a potential alternative to traditional chemotherapy, improving treatment specificity and efficacy.
Area of Science:
- Biochemistry
- Oncology
- Molecular Biology
Background:
- Pancreatic cancer is a highly lethal malignancy with limited effective treatments.
- Traditional chemotherapies like gemcitabine suffer from non-specific delivery and off-target effects.
- Highly potent cytotoxic agents, such as monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF), require targeted delivery systems.
Purpose of the Study:
- To evaluate the efficacy of aptamer-conjugated MMAE and MMAF for targeted delivery to pancreatic cancer cells.
- To assess the potential of aptamers as a novel platform for pancreatic cancer therapeutics.
Main Methods:
- Synthesized aptamers targeting the transferrin receptor (Waz) and epidermal growth factor receptor (E07).
- Conjugated MMAE and MMAF to the aptamers.
- Assayed the in vitro toxicity of these aptamer-drug conjugates on pancreatic cancer cell lines (Panc-1, MIA PaCa-2, BxPC3).
Main Results:
- Aptamer-drug conjugates demonstrated targeted toxicity against pancreatic cancer cell lines in vitro.
- The study confirmed the potential of aptamers for delivering cytotoxic payloads specifically to cancer cells.
- Results suggest aptamers offer advantages over antibodies for drug delivery due to synthetic production and small size.
Conclusions:
- Aptamer-mediated delivery of MMAE and MMAF is a viable strategy for targeting pancreatic cancer.
- This approach holds potential for developing more effective and specific pancreatic cancer therapies.
- Aptamers represent a promising chemical platform for next-generation cancer therapeutics.
More Related Videos
Related Concept Videos
01:24Modified-Release Drug Delivery Systems: Site-Targeted
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:19Modified-Release Drug Delivery Systems: Overview
01:23Modified-Release Drug Delivery Systems: Classification
01:30Modified-Release Drug Delivery Systems: Bioavailability
01:36Types of Toxins
Air pollutants, primarily gases, pose significant threats to respiratory health, leading to conditions like hypoxia, lung cancer, and in extreme cases, death.
Environmental pollutants like...